Corxel Pharmaceuticals closed a $287 million financing to advance global development of an oral GLP‑1 candidate licensed from China‑based Vincentage. The company said proceeds will fund phase 2/3 studies and global regulatory activities for a pill formulation it positions as comparable to injectable GLP‑1s for chronic weight management. Investors highlighted the continued capital appetite for obesity therapeutics and oral GLP‑1 franchises. The raise also reflects growing investor willingness to back late‑stage development of orally delivered incretin therapies, which could expand market access and simplify chronic care delivery if clinical results match injectable efficacy.